Elevation Oncology Announces Material Agreement & Board Changes
| Field | Detail |
|---|---|
| Company | Elevation Oncology, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, management-change, corporate-action
TL;DR
Elevation Oncology inked a new deal and shuffled execs/board on June 5th.
AI Summary
Elevation Oncology, Inc. announced on June 5, 2025, a material definitive agreement and changes in its board and officer composition. The company also disclosed information related to Regulation FD and submitted financial statements and exhibits. The filing also notes a former company name, 14ner Oncology, Inc., with a name change date of July 19, 2019.
Why It Matters
This filing indicates significant corporate actions, including a new agreement and potential leadership shifts, which could impact the company's strategic direction and operational focus.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and changes in directors/officers, which can introduce uncertainty or signal strategic shifts.
Key Players & Entities
- Elevation Oncology, Inc. (company) — Registrant
- June 5, 2025 (date) — Earliest event reported
- 14ner Oncology, Inc. (company) — Former company name
- July 19, 2019 (date) — Date of former company name change
FAQ
What is the nature of the material definitive agreement announced by Elevation Oncology?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What specific changes occurred regarding Elevation Oncology's directors or officers?
The filing states there were departures of directors or certain officers, election of directors, and appointment of certain officers, along with compensatory arrangements, but does not name the individuals involved or the exact changes.
What is the significance of the Regulation FD Disclosure item?
Regulation FD Disclosure indicates that the company is providing information that could be considered non-public and is making it available to the public to prevent selective disclosure.
What financial statements and exhibits are being submitted with this 8-K?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents of these documents are not detailed in the provided text.
What was Elevation Oncology's former name and when did the change occur?
Elevation Oncology, Inc. was formerly known as 14ner Oncology, Inc., and the name change occurred on July 19, 2019.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Elevation Oncology, Inc..